The pathogenesis of MG involves autoantibodies targeting neuromuscular junction proteins, including the acetylcholine receptor (AChR), muscle-specific kinase (MuSK), and low-density lipoprotein receptor-related protein 4 (LRP4), as well as thymic abnormalities and immune dysregulation influenced by genetic and environmental factors [4,8]. This evidence concerns the gene LRP4 and myasthenia gravis.